Form 4: Elevation Oncology CEO Joseph Ferra Jr. Reports Routine Stock Transactions

Elevation Oncology, Inc. CEO Joseph J. Ferra Jr. reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes, increasing his direct beneficial ownership.

Summary

• Joseph J. Ferra Jr., the Chief Executive Officer and a Director of Elevation Oncology, Inc. (ELEV), reported changes in his beneficial ownership of the company's common stock.
• On June 16, 2025, Mr. Ferra acquired 12,560 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently, he disposed of 4,627 shares of common stock at a price of $0.3854 per share, typically to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Ferra's direct beneficial ownership of Elevation Oncology common stock stands at 145,085 shares.
• The RSUs represent a contingent right to receive one share of common stock, with 25% having vested on June 16, 2022, and the remainder vesting quarterly at a rate of 1/16 of the total RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction (vesting and tax-related sale) that does not indicate significant positive or negative developments for the company.

Positives

• The vesting of 12,560 restricted stock units indicates the achievement of performance or time-based conditions, reflecting positively on the company's compensation structure and the CEO's continued equity alignment.
• Despite a sale for tax purposes, the net effect of the transactions was an increase in the CEO's direct beneficial ownership by 7,933 shares (12,560 acquired 4,627 disposed), demonstrating continued commitment to the company.

Negatives

• A portion of the vested shares (4,627 shares) was sold, which, while common for tax withholding, represents a reduction in direct ownership from the gross vested amount.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports changes in insider ownership.

Future Outlook

The document does not provide forward-looking statements or guidance beyond the implied continued vesting schedule of the remaining RSUs.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The transaction shows the CEO's continued equity alignment with the company, as his direct beneficial ownership increased net of the tax-related sale. This is a routine event and generally has minimal direct impact on shareholders.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued quarterly vesting of the remaining Restricted Stock Units (RSUs) as per the established schedule.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Stock Ownership, Restricted Stock Units, RSU Vesting, Elevation Oncology, ELEV, Joseph J. Ferra Jr., CEO, Director